Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/dme.14989 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A community-based approach to address lung cancer screening disparities in the black community using the Witness Project framework: development and pilot trial.
BMC Public Health
January 2025
Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Background: Disparities in lung cancer outcomes persist among Black Americans, necessitating targeted interventions to address screening inequities. This paper reports the development and refinement of Witness Project Lung, a community-based initiative tailored to the specific needs of the Black community, aiming to improve awareness and engagement with lung cancer screening.
Methods: Utilizing a user-centered design and guided by the original Witness Project framework - an evidence-based lay health advisor intervention program originally developed to increase knowledge and awareness about breast cancer risk and screening in the Black community and later trans-created to the cervical and colorectal cancer screening contexts - Witness Project Lung was developed and refined through qualitative input from key stakeholders in the Black faith community.
Unanchored simulated treatment comparison on survival outcomes using parametric and Royston-Parmar models with application to lenvatinib plus pembrolizumab in renal cell carcinoma.
BMC Med Res Methodol
January 2025
Clifton Insight, Bristol, UK.
Background: Population-adjusted indirect comparison using parametric Simulated Treatment Comparison (STC) has had limited application to survival outcomes in unanchored settings. Matching-Adjusted Indirect Comparison (MAIC) is commonly used but does not account for violation of proportional hazards or enable extrapolations of survival. We developed and applied a novel methodology for STC in unanchored settings.
View Article and Find Full Text PDFDihydropyrimidine Dehydrogenase Deficiency (DPYD) Genotyping-Guided Fluoropyrimidine-Based Adjuvant Chemotherapy for Breast Cancer. A Cost-Effectiveness Analysis.
Clin Drug Investig
January 2025
Pharmacy Department, Hamad Medical Corporation, Doha, 3050, Qatar.
Background And Objective: While standard doses of adjuvant fluoropyrimidine-based chemotherapies are generally safe for most patients, the risk of severe adverse drug reactions (ADRs) is increased for those with dihydropyrimidine dehydrogenase deficiency (DPYD), a genetic variation that affects drug metabolism. The objective of this study was to examine the cost effectiveness of offering DPYD pharmacogenetic-guided care, where genetic testing informs personalized dosing versus the current standard of care (SoC), which involves administering fluoropyrimidine-based therapies without prior genetic screening, for local or metastatic breast cancer patients in Qatar.
Methods: We developed a two-stage decision analysis, with an analytic tree model over a 6-month period, followed by a life-table Markov model over a lifetime horizon.
Long-term Double-J stenting is superior to short-term Single-J stenting in kidney transplantation.
PLoS One
January 2025
Division of Hepatobiliary and Transplantation Surgery, Department of Surgery, Erasmus MC Transplant Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Background And Objectives: Urological complications after kidney transplantation, due to the ureteroneocystostomy, are associated with significant morbidity, prolonged hospital stay and even mortality. Ureteral stents can minimize the number of complications but are not consistently used, as previous studies were retrospective in nature. We aim to prospectively determine the most effective stenting approach.
View Article and Find Full Text PDFAdding capivasertib to fulvestrant in patients with hormone receptor-positive advanced breast cancer: a cost-effectiveness analysis.
Front Pharmacol
January 2025
Department of Pharmacy, Huadong Hospital, Fudan University, Shanghai, China.
Article Synopsis
- Capivasertib, combined with fulvestrant, shows antitumor activity in hormone receptor-positive advanced breast cancer, but its cost-effectiveness is uncertain.
- A partitioned survival model evaluated the treatment's cost-effectiveness, revealing an incremental cost-utility ratio (ICUR) of $709,647 per quality-adjusted life-year (QALY) in the US, indicating it is not cost-effective.
- Sensitivity analyses confirmed that factors like overall survival rates and the drug's cost greatly influence these results, and findings for China also suggested the treatment is not cost-effective.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!